We experimentally analyzed KRAS mutations using ddPCR on the same 17 plasma samples from patients with late-stage pancreatic cancer, 8 patients with early-stage pancreatic cancer, and 20 individuals without cancer, using the same plasma input volumes used for the DREAMing analysis. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.